Tesamorelin Ipamorelin Dosage: A 2026 Dosing Guide

Tesamorelin and ipamorelin are both growth hormone secretagogues but work through different mechanisms and are dosed differently. This guide breaks down typical dosing ranges, timing considerations, reconstitution basics, and how to track both compounds accurately when used together or separately.

Table of Contents

• What Tesamorelin and Ipamorelin Actually Do
• Typical Tesamorelin Dosing Ranges
• Typical Ipamorelin Dosing Ranges
• Combining Tesamorelin and Ipamorelin
• Reconstitution and Injection Basics
• Monitoring Side Effects and Progress
• Tracking Your Protocol Without the Guesswork

What Tesamorelin and Ipamorelin Actually Do

Tesamorelin and ipamorelin both stimulate the body’s own growth hormone (GH) release, but they work through different pathways. Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH), meaning it binds to GHRH receptors in the pituitary and prompts a more sustained GH pulse. It’s FDA-approved specifically for reducing excess abdominal fat in HIV-associated lipodystrophy, and clinical trials measuring this indication found meaningful reductions in visceral adipose tissue over 26 weeks of use, according to the FDA-approved prescribing information (accessdata.fda.gov). Ipamorelin, by contrast, is a growth hormone secretagogue (a ghrelin mimetic) that selectively triggers GH release without significantly raising cortisol or prolactin, a selectivity profile documented in early pharmacological studies (pubmed.ncbi.nlm.nih.gov). Because they act on different receptors, some users stack them to try to produce a stronger, more naturalistic GH pulse than either compound alone. Understanding this mechanistic difference matters before you even think about dosage, since dosing one without appreciating how it interacts with the other can undercut the intended effect.

Typical Tesamorelin Dosing Ranges

The FDA-approved dose of tesamorelin for its approved indication is 2 mg administered as a single subcutaneous injection once daily, reconstituted with sterile water immediately before use, per the prescribing information (accessdata.fda.gov). In research and off-label peptide contexts, some protocols use doses ranging from 1 mg to 2 mg daily, often timed in the evening or before bed to align with the body’s natural nocturnal GH pulse. Because tesamorelin has a short half-life of roughly 26 to 38 minutes in circulation, consistent daily timing matters more than spacing doses far apart. Missing doses or injecting at wildly different times each day can blunt the cumulative effect researchers observed in trials, where measurable changes in visceral fat took 26 weeks to fully manifest. This is a compound where patience and consistency, not higher doses, drive results. A typical single-use vial contains 1 mg or 2 mg of lyophilized peptide, so accurate reconstitution volume is critical to hitting the intended dose reliably night after night.

Typical Ipamorelin Dosing Ranges

Ipamorelin doses used in research and self-directed peptide protocols commonly fall between 100 mcg and 300 mcg per injection, administered subcutaneously one to three times daily. Many protocols favor dosing around meals or before bed, since food intake can blunt the GH pulse that secretagogues like ipamorelin are designed to trigger. Unlike tesamorelin, ipamorelin has a very short plasma half-life — often cited around 2 hours — so multiple smaller doses spread through the day are more common than a single large dose. A frequently referenced starting point is 200 mcg twice daily, adjusted based on how a person responds and tolerates the compound. Because ipamorelin is dosed more frequently than tesamorelin, small errors in reconstitution math compound quickly across a week. Using a peptide reconstitution calculator to double check your mcg-per-unit conversion before drawing up a dose is one of the simplest ways to avoid under- or overdosing when running multiple daily injections.

Combining Tesamorelin and Ipamorelin

Stacking tesamorelin with ipamorelin is a common approach because the two compounds act on separate receptors — GHRH receptor versus ghrelin receptor — theoretically producing a more robust GH pulse than either alone. A typical combined protocol might use tesamorelin at 1-2 mg once daily in the evening, paired with ipamorelin at 200-300 mcg one to three times daily around meals. The logic mirrors the more extensively documented CJC-1295 and ipamorelin combination, where GHRH and ghrelin-mimetic peptides are paired for a similar reason; the dosing principles and rationale are covered in detail in a dedicated CJC-1295 & ipamorelin dosing guide. The key operational challenge with any stack is timing: overlapping injections without a clear schedule increases the risk of missed doses, duplicate doses, or confusion about which vial is running low. Anyone combining these compounds should build a simple daily schedule in advance rather than relying on memory, since the injection frequency roughly doubles compared to running either peptide alone.

Reconstitution and Injection Basics

Both tesamorelin and ipamorelin arrive as lyophilized (freeze-dried) powder in vials and must be reconstituted with bacteriostatic or sterile water before injection. The concentration you end up with depends entirely on how much diluent you add — for example, adding 2 mL of water to a 2 mg tesamorelin vial yields 1 mg/mL, while adding 3 mL yields roughly 0.67 mg/mL. For ipamorelin, a 5 mg vial reconstituted with 2 mL of water yields 2.5 mg/mL, meaning a 250 mcg dose is just 0.1 mL on an insulin syringe. Getting this math wrong is one of the most common errors in peptide self-administration, and it’s precisely why tools like a peptide calculator for dosing and reconstitution exist — they let you input vial size, diluent volume, and target dose to get an exact draw volume instead of estimating. Once reconstituted, both peptides should be stored refrigerated and used within the timeframe recommended on the product, as bacteriostatic water preservatives typically maintain sterility for about 28 days.

Monitoring Side Effects and Progress

Common side effects associated with tesamorelin include injection site redness, joint pain, and swelling, with peripheral edema and joint-related symptoms noted among the more frequently reported adverse events in clinical trial data (accessdata.fda.gov). Ipamorelin is generally described as having a milder side effect profile due to its receptor selectivity, though injection site reactions, headache, and flushing are still reported. Because GH secretagogues can gradually raise IGF-1 levels, periodic bloodwork is a reasonable way to confirm a protocol is working as intended rather than relying on subjective feel alone. Tracking symptoms alongside dose timing — noting whether soreness clusters around a particular injection site or whether nausea trends with a specific time of day — turns anecdotal side effects into actionable data. Users who log symptoms systematically over 30 days often notice patterns, such as fatigue correlating with under-dosing or site soreness clustering on overused injection spots, that are easy to miss when tracking is done from memory.

Tracking Your Protocol Without the Guesswork

Running two peptides with different half-lives, injection frequencies, and reconstitution math is exactly the kind of complexity that spreadsheets struggle to handle cleanly. Pep was built for this: it lets you log tesamorelin and ipamorelin as separate protocols with their own schedules, calculates reconstitution volumes so you’re not doing mental math with a syringe in hand, and rotates injection sites automatically so you’re not stacking doses in the same spot night after night. The app’s symptom logging feature lets you tag side effects like joint pain or injection site redness by compound, so if you’re stacking both peptides, you can actually tell which one is driving a given symptom. With inventory tracking, you’ll also get a heads-up before a vial runs low — useful when you’re juggling a once-daily tesamorelin shot and a two-or-three-times-daily ipamorelin schedule that draws down vials at very different rates. If you’re currently managing this by memory or in a notes app, it’s worth trying a system that was designed specifically for multi-compound peptide protocols at hellopep.io.

Frequently Asked Questions

What is a typical tesamorelin dose per day?

The FDA-approved dose is 2 mg injected subcutaneously once daily, though some off-label protocols use 1 mg. Consistency in daily timing matters more than dose size since results in clinical trials took 26 weeks to become measurable.

How much ipamorelin should I take?

Common doses range from 100 mcg to 300 mcg per injection, often given one to three times daily due to ipamorelin’s short roughly 2-hour half-life. Many protocols start around 200 mcg twice daily and adjust from there.

Can you take tesamorelin and ipamorelin together?

Yes, they’re commonly stacked since tesamorelin acts on GHRH receptors while ipamorelin acts on ghrelin receptors, potentially producing a stronger combined GH pulse. This does roughly double your injection frequency, so a clear schedule is important.

How do I know how much sterile water to add when reconstituting these peptides?

The amount of diluent determines your final concentration, so it depends on your target dose and vial size. Using a reconstitution calculator, like the one built into Pep, removes the guesswork and gives you an exact draw volume.

What are the most common side effects of tesamorelin and ipamorelin?

Tesamorelin has been associated with injection site reactions, joint pain, and swelling in clinical trial data. Ipamorelin’s side effect profile is generally milder due to its receptor selectivity, though injection site reactions and headache can still occur.